Barclays analyst Andrew Mok raised the firm’s price target on Privia Health (PRVA) to $23 from $22 and keeps an Equal Weight rating on the shares post the Q3 report. The company’s “prudence” in accruing performance in capitated contracts and shared savings began to pay off, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health’s Earnings Call Highlights Robust Growth
- Privia Health price target raised to $30 from $28 at Evercore ISI
- Privia Health price target raised to $31 from $30 at Citizens JMP
- Privia Health Reports Strong Q3 2025 Results
- Privia Health Group: Strong Financial Performance and Strategic Growth Justify Buy Rating